Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiology and Therapy
Published in: Cardiology and Therapy 1/2024

Open Access 21-02-2024 | Review

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?

Authors: Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari-Shafti

Published in: Cardiology and Therapy | Issue 1/2024

Login to get access

Abstract

Numerous genetic and epidemiologic studies have demonstrated an association between elevated levels of lipoprotein(a) (Lp[a]) and cardiovascular disease. As a result, lowering Lp(a) levels is widely recognized as a promising strategy for reducing the risk of new-onset coronary heart disease, stroke, and heart failure. Lp(a) consists of a low-density lipoprotein-like particle with covalently linked apolipoprotein A (apo[a]) and apolipoprotein B-100, which explains its pro-thrombotic, pro-inflammatory, and pro-atherogenic properties. Lp(a) serum concentrations are genetically determined by the apo(a) isoform, with shorter isoforms having a higher rate of particle synthesis. To date, there are no approved pharmacological therapies that effectively reduce Lp(a) levels. Promising treatment approaches targeting apo(a) expression include RNA-based drugs such as pelacarsen, olpasiran, SLN360, and lepodisiran, which are currently in clinical trials. In this comprehensive review, we provide a detailed overview of RNA-based therapeutic approaches and discuss the recent advances and challenges of RNA therapeutics specifically designed to reduce Lp(a) levels and thus the risk of cardiovascular disease.
Literature
1.
Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther Elsevier Ltd. 2017;25:1069–75.CrossRef
2.
3.
4.
Mollocana-Lara EC, Ni M, Agathos SN, Gonzales-Zubiate FA. The infinite possibilities of RNA therapeutics. J Ind Microbiol Biotechnol. 2021;48: kuab063.PubMedPubMedCentralCrossRef
5.
6.
Igarashi J, Niwa Y, Sugiyama D. Research and development of oligonucleotide therapeutics in Japan for rare diseases. Futur Rare Dis. 2022;2:1–14.
7.
Mullard A. FDA approves fifth RNAi drug - Alnylam’s next-gen hATTR treatment. Nat Rev Drug Discov. 2022;21(8):548–9.PubMed
8.
Bireley JD, Morren JA. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS). Expert Opin Investig Drugs. 2023;32:677–83 (Taylor & Francis).PubMedCrossRef
9.
10.
Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630–43.ADSPubMedCrossRef
11.
Sinning D, Landmesser U. Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA Treatment targeting PCSK9 (Inclisiran). Curr Cardiol Rep. 2020;22:176.PubMedPubMedCentralCrossRef
12.
Kronenberg F. Lipoprotein(a). In: von Eckardstein A, Binder CJ, editors. Prev treat atheroscler improv state-of-the-art manag search nov targets. Cham: Springer International Publishing; 2022. p. 201–32.
13.
Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): When and how to measure it. Ann Clin Biochem. 2021;58:16–21.PubMedCrossRef
14.
Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting Lipoprotein(a) production in individuals with elevated plasma Lipoprotein(a) levels. J Am Med Assoc. 2022;327:1679–87.CrossRef
15.
16.
Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17:1447–547.PubMedPubMedCentralCrossRef
17.
18.
Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the Apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011;4:565–73 (American Heart Association).PubMedCrossRef
19.
20.
21.
Bonham MA, Brown S, Boyd AL, Brown PH, Bruckenstein DA, Hanvey JC, et al. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res. 1995;23:1197–203 (England).PubMedPubMedCentralCrossRef
22.
23.
24.
25.
26.
27.
28.
Gait MJ, Agrawal S. Introduction and history of the chemistry of nucleic acids therapeutics BT—antisense RNA design, delivery, and analysis. In: Arechavala-Gomeza V, Garanto A, editors. Methods Mol Biol. New York: Springer, US; 2022. p. 3–31.
29.
Xu W, Jiang X, Huang L. RNA interference technology. Compr Biotechnol. Elsevier; 2019. p. 560–75.
30.
Zogg H, Singh R, Ro S. Current advances in RNA therapeutics for human diseases. Int J Mol Sci. 2022.
31.
Al Musaimi O, Al Shaer D, Albericio F, de la Torre BG. 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). Switzerland; 2023;16.
32.
33.
34.
35.
36.
37.
Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7:166.PubMedPubMedCentralCrossRef
38.
Duan Q, Hu T, Zhu Q, Jin X, Chi F, Chen X. How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development. Front Immunol. 2022.
39.
40.
41.
42.
43.
Rupaimoole R, Han H-D, Lopez-Berestein G, Sood AK. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011;30(6):368–70.PubMedPubMedCentralCrossRef
44.
45.
46.
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102–14.PubMedCrossRef
47.
48.
Guerriaud M, Kohli E. RNA-based drugs and regulation: toward a necessary evolution of the definitions issued from the European union legislation. Front Med. 2022.
49.
50.
Kuijper EC, Bergsma AJ, Pijnappel WWMP, Aartsma-Rus A. Opportunities and challenges for antisense oligonucleotide therapies. J Inherit Metab Dis. 2021;44:72–87 (John Wiley & Sons, Ltd).PubMedCrossRef
51.
Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio. 2008;2: GRSB.S418 (SAGE Publications Ltd STM).CrossRef
52.
Meng M, Schmidtgall B, Ducho C. Enhanced stability of DNA oligonucleotides with partially Zwitterionic backbone structures in biological media. Molecules. 2018;23(11):2941 (Switzerland).PubMedPubMedCentralCrossRef
53.
Irie A, Sato K, Hara RI, Wada T, Shibasaki F. An artificial cationic oligosaccharide combined with phosphorothioate linkages strongly improves siRNA stability. Sci Rep. 2020;10:14845.ADSPubMedPubMedCentralCrossRef
54.
55.
56.
Liu A, Wang X. The pivotal role of chemical modifications in mRNA therapeutics. Front Cell Dev Biol. 2022.
57.
Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46–51.PubMedCrossRef
58.
Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 2002;30:1911–8.PubMedPubMedCentralCrossRef
59.
Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA. 1997;94:2620–5 (United States).ADSPubMedPubMedCentralCrossRef
60.
Gareri C, Polimeni A, Giordano S, Tammè L, Curcio A, Indolfi C. Antisense oligonucleotides and small interfering RNA for the treatment of dyslipidemias. J Clin Med. 2022.
61.
Deleavey GF, Watts JK, Damha MJ. Chemical modification of siRNA. Curr Protoc Nucleic Acid Chem. 2009;39:16.3.1-16.3.22 (John Wiley & Sons, Ltd).CrossRef
62.
Varley AJ, Hammill ML, Salim L, Desaulniers JP. Effects of chemical modifications on siRNA strand selection in mammalian cells. Nucleic Acid Ther. 2020;30:229–36.PubMedCrossRef
63.
64.
Kim SC, Sekhon SS, Shin W-R, Ahn G, Cho B-K, Ahn J-Y, et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18:1–8.PubMedCrossRef
65.
66.
Fan J, Feng Y, Zhang R, Zhang W, Shu Y, Zeng Z, et al. A simplified system for the effective expression and delivery of functional mature microRNAs in mammalian cells. Cancer Gene Ther. 2020;27:424–37.PubMedCrossRef
67.
Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol. 2014;43:78–89 (SAGE Publications Inc).PubMedCrossRef
68.
Anderson BA, Freestone GC, Low A, De-Hoyos CL, Drury WJ III, Østergaard ME, et al. Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. Nucleic Acids Res. 2021;49:9026–41.PubMedPubMedCentralCrossRef
69.
Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20:513–24 (United States).PubMedPubMedCentralCrossRef
70.
71.
72.
73.
Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, et al. Off-target effects by siRNA can induce toxic phenotype. RNA. 2006;12:1188–96.PubMedPubMedCentralCrossRef
74.
Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003;21:635–7 (United States).PubMedCrossRef
75.
Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, et al. Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs. Drug Metab Dispos. 2022;50:879–87.PubMedCrossRef
76.
77.
Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28:1759–71.PubMedPubMedCentralCrossRef
78.
Willoughby JLS, Chan A, Sehgal A, Butler JS, Nair JK, Racie T, et al. Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression. Mol Ther. 2018;26:105–14.PubMedCrossRef
79.
Zhang M, Huang Y. siRNA modification and delivery for drug development. Trends Mol Med Elsevier. 2022;28:892–3.CrossRef
80.
81.
Ranasinghe P, Addison ML, Dear JW, Webb DJ. Small interfering RNA: discovery, pharmacology and clinical development—an introductory review. Br J Pharmacol. 2023;180:2697–720 (John Wiley & Sons, Ltd).PubMedCrossRef
82.
83.
Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, et al. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immunity Inflamm Dis. 2023;11: e807 (John Wiley & Sons, Ltd).CrossRef
84.
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circu Am Heart Assoc. 2022;145:e153-639.
85.
Hajar R. Risk factors for coronary artery disease: historical perspectives. Hear Views. 2017;18:109–14.CrossRef
86.
87.
88.
89.
Tomasoni D, Bonfioli GB, Aimo A, Adamo M, Canepa M, Inciardi RM, et al. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. Front Cardiovasc Med. 2023.
90.
Severi D, Palumbo G, Spina E, Iovino A, Nolano M, Manganelli F, et al. A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment. Neurol Sci. 2023;44:1419–22.PubMedCrossRef
91.
Tardif J-C, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401–12.PubMedPubMedCentralCrossRef
92.
Coelho T, Marques W Jr, Dasgupta NR, Chao C-C, Parman Y, França MC Jr, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330:1448–58.PubMedCrossRef
93.
Lazarte J, Hegele RA. Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Rev Cardiovasc Ther. 2021;19:685–93 (Taylor & Francis).PubMedCrossRef
94.
Chambergo-Michilot D, Alur A, Kulkarni S, Agarwala A. Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes. Vasc Health Risk Manag. 2022;18:73–80 (Dove Medical Press).PubMedPubMedCentralCrossRef
95.
96.
Merćep I, Friščić N, Strikić D, Reiner Ž. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9—a narrative review. Tomlinson B, editor. Cardiovasc Ther. Hindawi; 2022;2022:8129513.
97.
Yang J. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol. 2019;12:95–9 (Taylor & Francis).PubMedCrossRef
98.
Nie T, Heo Y-A, Shirley M. Vutrisiran: a review in polyneuropathy of hereditary transthyretin-mediated amyloidosis. Drugs. 2023;83:1425–32.PubMedCrossRef
99.
100.
101.
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289–97.PubMedCrossRef
102.
Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults E. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
103.
104.
105.
Tomlinson B, Patil NG, Fok M, Lam CWK. Role of PCSK9 inhibitors in patients with familial hypercholesterolemia. Endocrinol Metab (Seoul, Korea). 2021;36:279–95 (Korea (South)).CrossRef
106.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–88.PubMedCrossRef
107.
Pang J, Chan DC, Watts GF. The knowns and unknowns of contemporary statin therapy for familial hypercholesterolemia. Curr Atheroscler Rep. 2020;22:64 (United States).PubMedPubMedCentralCrossRef
108.
Qiao YN, Zou YL, Guo SD. Low-density lipoprotein particles in atherosclerosis. Front Physiol. 2022;13:1–15.CrossRef
109.
Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martinez I, Guzman E. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential. Ther Clin Risk Manag. 2020;16:1031–7.PubMedPubMedCentralCrossRef
110.
111.
112.
Calcaterra I, Lupoli R, Di Minno A, Di Minno MND. Volanesorsen to treat severe hypertriglyceridaemia: a pooled analysis of randomized controlled trials. Eur J Clin Invest. 2022;52: e13841 (John Wiley & Sons, Ltd).PubMedPubMedCentralCrossRef
113.
Akoumianakis I, Zvintzou E, Kypreos K, Filippatos TD. ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets. Curr Atheroscler Rep. 2021;23:20.PubMedCrossRef
114.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554–68.PubMedPubMedCentralCrossRef
115.
Robinson C, Pham C, Zamarripa AM, Dugay CS, Lee CA, Berger AA, et al. Inotersen to treat polyneuropathy associated with hereditary transthyretin (hATTR) amyloidosis. Heal Psychol Res. 2022;10:1–8.
116.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021;20:49–59.PubMedCrossRef
117.
Obici L, Ajroud-Driss S, Lin K-P, Berk JL, Gillmore JD, Kale P, et al. Impact of vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Neurol Ther. 2023;12:1759–75.PubMedPubMedCentralCrossRef
118.
Shapiro S, Benson G, Evans G, Harrison C, Mangles S, Makris M. Cardiovascular disease in hereditary haemophilia: the challenges of longevity. Br J Haematol. 2022;197:397–406 (John Wiley & Sons, Ltd).PubMedPubMedCentralCrossRef
119.
Kamphuisen PW, ten Cate H. Cardiovascular risk in patients with hemophilia. Blood. 2014;123:1297–301.PubMedCrossRef
120.
Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You C-W, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023;401:1427–37 (Elsevier).PubMedCrossRef
121.
122.
Fatica EM, Meeusen JW, Vasile VC, Jaffe AS, Donato LJ. Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. Clin Biochem. 2020;86:45–51.PubMedCrossRef
123.
Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28:96–103 (Springer US).PubMedCrossRef
124.
Guertin J, Kaiser Y, Manikpurage H, Perrot N, Bourgeois R, Couture C, et al. Sex-specific associations of genetically predicted circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene expression levels with cardiovascular outcomes: Mendelian randomization and observational analyses. Circ Genomic Precis Med. 2021;14:E003271.CrossRef
125.
Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020;287:2–18.PubMedCrossRef
126.
Hardy J, Niman S, Goldfaden RF, Ashchi M, Bisharat M, Huston J, et al. A review of the clinical pharmacology of pelacarsen: a Lipoprotein(a)-lowering agent. Am J Cardiovasc Drugs. 2022;22:47–54 (Springer International Publishing).PubMedCrossRef
127.
Mackinnon LT, Hubinger L, Lepre F. Effects of physical activity and diet on lipoprotein(a). Med Sci Sport Exerc. 1997;29:1429–36.CrossRef
128.
Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28 (Massachusetts Medical Society).PubMedCrossRef
129.
Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. J Clin Lipidol. 2018;12:122-129.e2.PubMedCrossRef
130.
Nakajima K, Hata Y. Intraindividual variations in Lipoprotein (a) levels and factors related to these changes. J Atheroscler Thromb. 1996;2:96–106.PubMedCrossRef
131.
Riches K, Porter KE. Lipoprotein(a): Cellular effects and molecular mechanisms. Cholesterol. 2012;2012.
132.
Yano Y, Shimokawa K, Okada Y, Noma A. Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem. 1997;45:559–68.PubMedCrossRef
133.
von Zychlinski A, Kleffmann T, Williams MJA, McCormick SP. Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. J Proteomics. 2011;74:2881–91 (Elsevier B.V.).CrossRef
134.
135.
Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103:76–84.PubMedPubMedCentral
136.
Flick MJ, Bugge TH. Plasminogen–receptor KT: plasminogen activation and beyond. J Thromb Haemost. 2017;15:150–4 (John Wiley & Sons, Ltd).PubMedCrossRef
137.
Draxler DF, Sashindranath M, Medcalf RL. Plasmin: a modulator of immune function. Semin Thromb Hemost. 2017;43:143–53.PubMedCrossRef
138.
Edelberg JM, Pizzo SV. Lipoprotein (a) in the regulation of fibrinolysis. J Atheroscler Thromb. 1995;2 Suppl 1:S5–7 (Japan).PubMedCrossRef
139.
Jenkins AJ, Kostner KM, Kostner GM. Lipoprotein(a): structure, metabolism, and pathophysiology BT—Lipoproteins in diabetes Mellitus. In: Jenkins AJ, Toth PP, Lyons TJ, editors. New York. New York: Springer; 2014. p. 141–55.
140.
Ugovšek S, Šebeštjen M. Lipoprotein(a)-the crossroads of atherosclerosis, atherothrombosis and inflammation. Biomolecules. 2021;12:26 (Switzerland).PubMedPubMedCentralCrossRef
141.
142.
Litvinov RI, Pieters M, de Lange-Loots Z, Weisel JW. Fibrinogen and Fibrin BT - Macromolecular Protein Complexes III: Structure and Function. In: Harris JR, Marles-Wright J, editors. Cham: Springer International Publishing; 2021. p. 471–501.
143.
Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16:305–18 (Springer US).PubMedCrossRef
144.
van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, et al. Oxidized phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611–24.PubMedPubMedCentralCrossRef
145.
Schnitzler JG, Poels K, Stiekema LCA, Yeang C, Tsimikas S, Kroon J, et al. Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. Int J Cardiol. 2020;315:81–5.PubMedCrossRef
146.
Stiekema LCA, Prange KHM, Hoogeveen RM, Verweij SL, Kroon J, Schnitzler JG, et al. Potent lipoprotein (a) lowering following apolipoprotein (a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein (a). Eur Heart J. 2020;41:2262–71.PubMedPubMedCentralCrossRef
147.
Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis. JAMA Cardiol. 2018;3:619–27.PubMedPubMedCentralCrossRef
148.
Lamina C, Kronenberg F, Lp(a)-GWAS-Consortium. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis. JAMA Cardiol. 2019;4:575–9.PubMedPubMedCentralCrossRef
149.
Scharnagl H, Stojakovic T, Dieplinger B, Dieplinger H, Erhart G, Kostner GM, et al. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;289:206–13.PubMedCrossRef
150.
151.
Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J. 2020;13:753–7.PubMedPubMedCentralCrossRef
152.
153.
Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: Historical perspective and recent advances. Curr Atheroscler Rep. 2015;17.
154.
Julius U, Tselmin S, Schatz U, Fischer S, Birkenfeld AL, Bornstein SR. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels. Atheroscler Suppl. 2019;40:1–7.PubMedCrossRef
155.
Waldmann E, Parhofer KG. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology. 2019;51:227–32.PubMedCrossRef
156.
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41:2275–84.PubMedCrossRef
157.
Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313–9.PubMedCrossRef
158.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392:1211–320.CrossRef
159.
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statins and increases in Lp(a): an inconvenient truth that needs attention. Eur Heart J. 2020;41:192–3.PubMedCrossRef
160.
Ruscica M, Greco MF, Ferri N, Corsini A. Lipoprotein(a) and PCSK9 inhibition: clinical evidence. Eur Hear J Suppl. 2020;22:L53–6.CrossRef
161.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22 (Massachusetts Medical Society).PubMedCrossRef
162.
O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–92 (American Heart Association).PubMedCrossRef
163.
Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374–92.PubMedCrossRef
164.
Langsted A, Nordestgaard BG. Antisense Oligonucleotides Targeting Lipoprotein(a). Curr Atheroscler Rep. 2019;21:1–7.CrossRef
165.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244–55 (Massachusetts Medical Society).PubMedCrossRef
166.
167.
O’Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855–64 (Massachusetts Medical Society).PubMedCrossRef
168.
169.
170.
Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering RNA targeting Lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330:2075–83.PubMedCrossRef
171.
172.
173.
Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, et al. Effect of pelacarsen on Lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79:1035–46.PubMedCrossRef
174.
175.
Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472–83 (Elsevier Ltd).PubMedCrossRef
176.
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239–53 (Elsevier Ltd).PubMedCrossRef
177.
O’Donoghue ML, López JAG, Knusel B, Gencer B, Wang H, Wu Y, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events and lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61–9 (Elsevier Inc.).PubMedCrossRef
178.
Koren MJ, Moriarty PM, Neutel J, Baum SJ, Hernandez-Illas M, Weintraub HS, et al. Abstract 13951: safety, tolerability and efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a). Circulation. 2020;142:A13951–A13951 (American Heart Association).CrossRef
179.
180.
ClinicalTrials.gov. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a). NCT05581303. 2022.
181.
Rider DA, Eisermann M, Löffler K, Aleku M, Swerdlow DI, Dames S, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240–7.PubMedCrossRef
182.
Rider D, Chivers S, Aretz J, Eisermann M, Löffler K, Hauptmann J, et al. Preclinical toxicological assessment of a novel siRNA, SLN360, targeting elevated Lipoprotein (a) in Cardiovascular Disease. Toxicol Sci. 2022;189:237–49.PubMedPubMedCentralCrossRef
183.
ClinicalTrials.gov. A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a). NCT04606602. 2020. Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT04606602
184.
Sheridan C. RNA drugs lower lipoprotein(a) and genetically driven cholesterol. Nat Biotechnol. 2022;40:983–5.PubMedCrossRef
185.
186.
Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982–94.PubMedCrossRef
187.
188.
Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? BioEssays. 2003;25:72–8 (United States).PubMedCrossRef
189.
Segatto M, Di Giovanni A, Marino M, Pallottini V. Analysis of the protein network of cholesterol homeostasis in different brain regions: an age and sex dependent perspective. J Cell Physiol. 2013;228:1561–7 (United States).PubMedCrossRef
190.
Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, et al. Statins and the brain: more than lipid lowering agents? Curr Neuropharmacol. 2019;17:59–83.PubMedPubMedCentralCrossRef
191.
Park I-H, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, et al. Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging. 2003;24:637–43.PubMedCrossRef
192.
Björkhem I, Meaney S, Fogelman AM. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24:806–15.PubMedCrossRef
193.
Hussain G, Wang J, Rasul A, Anwar H, Imran A, Qasim M, et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 2019;18:26.PubMedPubMedCentralCrossRef
194.
Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: mendelian randomisation study. BMJ. 2017;357: j1648.PubMedPubMedCentralCrossRef
195.
Adhikari A, Tripathy S, Chuzi S, Peterson J, Stone NJ. Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies. J Clin Lipidol. 2021;15:22-32.e12.PubMedCrossRef
196.
Trompet S, van Vliet P, de Craen AJM, Jolles J, Buckley BM, Murphy MB, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257:85–90.PubMedCrossRef
197.
Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.PubMedCrossRef
198.
Agrawal S, Kandimalla ER. Role of Toll-like receptors in antisense and siRNA [corrected]. Nat Biotechnol. 2004;22:1533–7 (United States).PubMedCrossRef
199.
ClinicalTrials.gov. A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein. NCT02414594. 2015. Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT02414594
200.
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2010;375:998–1006 (England).PubMedCrossRef
201.
McGowan MP, Tardif J-C, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7: e49006.ADSPubMedPubMedCentralCrossRef
202.
Kastelein JJP, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729–35 (United States).PubMedCrossRef
203.
Wong E, Goldberg T. Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. P T. 2014;39:119–22.PubMedPubMedCentral
204.
Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2015;35:689–99 (American Heart Association).PubMedPubMedCentralCrossRef
205.
Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9:301–15.PubMedPubMedCentralCrossRef
206.
207.
Tsimikas S. A test in context: lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711.PubMedCrossRef
Metadata
Title
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
Authors
Henriette Thau
Sebastian Neuber
Maximilian Y. Emmert
Timo Z. Nazari-Shafti
Publication date
21-02-2024
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 1/2024
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-024-00353-w

Other articles of this Issue 1/2024

Cardiology and Therapy 1/2024 Go to the issue

Original Research

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago

Review

The Clear Value of Coronary Artery Calcification Evaluation on Non-Gated Chest Computed Tomography for Cardiac Risk Stratification

Brief Report

Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease

Original Research

Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization

Review

Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy

Original Research

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits